The global Acute Migraine Drugs market size was valued at USD 2165.3 million in 2022 and is forecast to a readjusted size of USD 3473.9 million by 2029 with a CAGR of 7.0% during review period.
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.
This report is a detailed and comprehensive analysis for global Acute Migraine Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Acute Migraine Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2018-2029
Global Acute Migraine Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2018-2029
Global Acute Migraine Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (USD/Unit), 2018-2029
Global Acute Migraine Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Unit), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Acute Migraine Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Acute Migraine Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J
Triptans
NSAIDs
Others
Hospital Pharmacies
Drug Stores
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Strengths:
- Increasing demand for effective migraine treatments, driven by rising prevalence of chronic migraines globally.
- Advancements in drug formulations and delivery mechanisms, offering more efficient and personalized treatment options.
Weaknesses:
- High cost of new migraine drugs, limiting accessibility for certain patient populations.
- Side effects and limited efficacy of some drugs, leading to patient dissatisfaction and discontinuation.
Opportunities:
- Growth in emerging markets where migraine awareness and healthcare access are improving.
- Expansion of biologic and CGRP inhibitors, offering new avenues for treatment and market growth.
Threats:
- Generic competition, particularly for older drug classes, reducing market share for branded products.
- Regulatory challenges and lengthy approval processes for new drugs, delaying time-to-market and innovation.
Political:
- Government policies and healthcare regulations impacting the approval and reimbursement of migraine drugs.
- Political stability and public health initiatives in emerging markets influencing the accessibility of new treatments.
Economic:
- Rising healthcare expenditures, particularly in developed countries, driving demand for migraine treatments.
- Economic downturns affecting patient spending power and limiting access to expensive, newer therapies.
Social:
- Growing awareness of migraine as a chronic condition, increasing patient demand for treatment options.
- Shifts in patient preferences towards more personalized, non-invasive treatments and preventive therapies.
Technological:
- Advancements in drug delivery systems and digital health tools, enabling better treatment outcomes and patient monitoring.
- Innovations in biologics and CGRP inhibitors driving new treatment options in the acute migraine market.
Environmental:
- Sustainability concerns influencing the production and packaging of pharmaceutical drugs.
- Environmental regulations affecting the disposal of pharmaceutical waste and drug manufacturing practices.
Legal:
- Stringent intellectual property laws protecting new migraine drugs but potentially leading to higher costs for patients.
- Legal challenges related to patent expirations and generic competition impacting market dynamics.
Suppliers:
- Pharmaceutical companies developing innovative migraine treatments, including biologics and small molecules.
- Raw material suppliers providing active pharmaceutical ingredients (APIs) for drug production.
Inputs:
- Research and clinical trial data driving drug formulation and approval processes.
- Regulatory guidelines and market demands shaping drug development and marketing strategies.
Process:
- Drug discovery, development, and clinical testing to bring new migraine treatments to market.
- Manufacturing, packaging, and distribution processes ensuring drug availability to healthcare providers and patients.
Outputs:
- Approved migraine drugs, including acute treatments and preventive therapies, reaching the market.
- Post-market data on drug efficacy, side effects, and patient outcomes informing future improvements.
Customers:
- Healthcare providers, including neurologists and primary care physicians, prescribing migraine drugs.
- Patients suffering from acute migraines, seeking effective and affordable treatments.
Threat of New Entrants:
- High barriers to entry, including significant R&D costs and regulatory requirements, limiting the number of new competitors.
- Patent protections for existing drugs providing a temporary competitive advantage, deterring new entrants.
Bargaining Power of Suppliers:
- Limited number of suppliers for specialized APIs and biologics, giving them higher bargaining power.
- Dependence on quality and regulatory standards for drug ingredients, increasing supplier leverage in pricing and supply chain management.
Bargaining Power of Buyers:
- Growing patient demand for effective and affordable treatments enhances bargaining power, especially in price-sensitive markets.
- Increasing number of generic alternatives for older drugs provides buyers with more treatment options and negotiation power.
Threat of Substitutes:
- Non-pharmaceutical treatments such as lifestyle changes, alternative therapies, and digital health solutions present viable substitutes.
- The rise of over-the-counter medications and preventive treatments like CGRP inhibitors reduces reliance on acute treatment options.
Industry Rivalry:
- Intense competition among major pharmaceutical companies developing acute migraine drugs, driving innovation but also price pressures.
- Constant innovation in drug efficacy and delivery methods leads to high competitive rivalry for market share among established players.
Raw Material Suppliers:
- Suppliers of active pharmaceutical ingredients (APIs) and excipients, which are critical for the production of migraine drugs.
- Dependence on high-quality, regulated sources of materials for biologics, which could impact supply chains and production timelines.
Research and Development:
- Ongoing investment in clinical trials and R&D to develop novel acute migraine treatments, such as CGRP inhibitors and other biologics.
- The need for collaboration between pharmaceutical companies and research institutions to accelerate the discovery of more effective therapies.
Regulatory Bodies:
- Regulatory approvals from agencies like the FDA and EMA significantly influence the market by determining the speed and success of drug launches.
- Changing regulatory standards for drug safety, efficacy, and manufacturing processes could impact the development timelines and cost structures for migraine treatments.
Technology Providers:
- Technological advancements in drug formulation, delivery systems, and clinical trial management are essential for speeding up the development of migraine drugs.
- Partnerships with tech companies to integrate AI and digital health tools into treatment strategies, which could streamline drug discovery and patient monitoring.
Manufacturers:
- Pharmaceutical companies involved in the large-scale production of acute migraine drugs, including new biologics and small molecules.
- Advanced manufacturing processes and quality control measures essential to meet regulatory standards for both branded and generic migraine drugs.
Distribution Channels:
- Established distribution networks, including wholesalers, pharmacies, and healthcare providers, ensuring drugs reach a global patient base.
- Growing trend of direct-to-patient distribution models, such as home delivery services for prescribed migraine medications.
Marketing and Sales:
- Intensive marketing campaigns targeting healthcare professionals and patients to raise awareness about new and effective migraine treatments.
- Increasing role of digital marketing and social media in educating patients and physicians, driving demand for specific migraine therapies.
Partnerships and Collaborations:
- Strategic partnerships between pharmaceutical companies and healthcare providers to offer bundled services or combined therapeutic solutions for migraines.
- Collaboration with research institutions and tech companies to develop next-gen therapies, including personalized treatments based on genetic data.
End Users (Patients):
- Patients seeking effective and fast-acting treatments for acute migraines, with growing awareness of available drug options.
- Increasing demand for personalized treatments, such as biologics and CGRP inhibitors, tailored to individual patient profiles.
Healthcare Providers:
- Physicians and neurologists prescribing acute migraine drugs based on patient severity, history, and treatment preferences.
- Growing use of digital health tools and telemedicine by healthcare providers to monitor and manage migraine treatment outcomes.
Pharmacies and Retailers:
- Pharmacies acting as key distribution points, offering over-the-counter solutions and prescription drugs for acute migraine relief.
- Retailers leveraging e-commerce platforms to increase access to migraine medications, especially in regions with limited access to healthcare providers.
Insurance and Payers:
- Insurance companies and government payers playing a critical role in determining the affordability and reimbursement of migraine treatments.
- Increasing negotiations between pharmaceutical companies and payers to reduce drug costs and expand coverage for high-priced biologics.
Chapter 1, to describe Acute Migraine Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Acute Migraine Drugs, with price, sales, revenue and global market share of Acute Migraine Drugs from 2018 to 2023.
Chapter 3, the Acute Migraine Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acute Migraine Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Acute Migraine Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Acute Migraine Drugs.
Chapter 14 and 15, to describe Acute Migraine Drugs sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Acute Migraine Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Acute Migraine Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Triptans
1.3.3 NSAIDs
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Acute Migraine Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Drug Stores
1.5 Global Acute Migraine Drugs Market Size & Forecast
1.5.1 Global Acute Migraine Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Acute Migraine Drugs Sales Quantity (2018-2029)
1.5.3 Global Acute Migraine Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Acute Migraine Drugs Product and Services
2.1.4 GSK Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 GSK Recent Developments/Updates
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business
2.2.3 Teva Acute Migraine Drugs Product and Services
2.2.4 Teva Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Teva Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Acute Migraine Drugs Product and Services
2.3.4 Pfizer Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Acute Migraine Drugs Product and Services
2.4.4 Novartis Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis Recent Developments/Updates
2.5 Sun Pharma
2.5.1 Sun Pharma Details
2.5.2 Sun Pharma Major Business
2.5.3 Sun Pharma Acute Migraine Drugs Product and Services
2.5.4 Sun Pharma Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Sun Pharma Recent Developments/Updates
2.6 Grunenthal
2.6.1 Grunenthal Details
2.6.2 Grunenthal Major Business
2.6.3 Grunenthal Acute Migraine Drugs Product and Services
2.6.4 Grunenthal Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Grunenthal Recent Developments/Updates
2.7 Endo Pharmaceuticals
2.7.1 Endo Pharmaceuticals Details
2.7.2 Endo Pharmaceuticals Major Business
2.7.3 Endo Pharmaceuticals Acute Migraine Drugs Product and Services
2.7.4 Endo Pharmaceuticals Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Endo Pharmaceuticals Recent Developments/Updates
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Acute Migraine Drugs Product and Services
2.8.4 Merck Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Merck Recent Developments/Updates
2.9 J & J
2.9.1 J & J Details
2.9.2 J & J Major Business
2.9.3 J & J Acute Migraine Drugs Product and Services
2.9.4 J & J Acute Migraine Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 J & J Recent Developments/Updates
3 Competitive Environment: Acute Migraine Drugs by Manufacturer
3.1 Global Acute Migraine Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Acute Migraine Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Acute Migraine Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Acute Migraine Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Acute Migraine Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Acute Migraine Drugs Manufacturer Market Share in 2022
3.5 Acute Migraine Drugs Market: Overall Company Footprint Analysis
3.5.1 Acute Migraine Drugs Market: Region Footprint
3.5.2 Acute Migraine Drugs Market: Company Product Type Footprint
3.5.3 Acute Migraine Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Acute Migraine Drugs Market Size by Region
4.1.1 Global Acute Migraine Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Acute Migraine Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Acute Migraine Drugs Average Price by Region (2018-2029)
4.2 North America Acute Migraine Drugs Consumption Value (2018-2029)
4.3 Europe Acute Migraine Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Acute Migraine Drugs Consumption Value (2018-2029)
4.5 South America Acute Migraine Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Acute Migraine Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Acute Migraine Drugs Sales Quantity by Type (2018-2029)
5.2 Global Acute Migraine Drugs Consumption Value by Type (2018-2029)
5.3 Global Acute Migraine Drugs Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Acute Migraine Drugs Sales Quantity by Application (2018-2029)
6.2 Global Acute Migraine Drugs Consumption Value by Application (2018-2029)
6.3 Global Acute Migraine Drugs Average Price by Application (2018-2029)
7 North America
7.1 North America Acute Migraine Drugs Sales Quantity by Type (2018-2029)
7.2 North America Acute Migraine Drugs Sales Quantity by Application (2018-2029)
7.3 North America Acute Migraine Drugs Market Size by Country
7.3.1 North America Acute Migraine Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Acute Migraine Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Acute Migraine Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Acute Migraine Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Acute Migraine Drugs Market Size by Country
8.3.1 Europe Acute Migraine Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Acute Migraine Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Acute Migraine Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Acute Migraine Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Acute Migraine Drugs Market Size by Region
9.3.1 Asia-Pacific Acute Migraine Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Acute Migraine Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Acute Migraine Drugs Sales Quantity by Type (2018-2029)
10.2 South America Acute Migraine Drugs Sales Quantity by Application (2018-2029)
10.3 South America Acute Migraine Drugs Market Size by Country
10.3.1 South America Acute Migraine Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Acute Migraine Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Acute Migraine Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Acute Migraine Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Acute Migraine Drugs Market Size by Country
11.3.1 Middle East & Africa Acute Migraine Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Acute Migraine Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Acute Migraine Drugs Market Drivers
12.2 Acute Migraine Drugs Market Restraints
12.3 Acute Migraine Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Acute Migraine Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Acute Migraine Drugs
13.3 Acute Migraine Drugs Production Process
13.4 Acute Migraine Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Acute Migraine Drugs Typical Distributors
14.3 Acute Migraine Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Acute Migraine Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Acute Migraine Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. GSK Basic Information, Manufacturing Base and Competitors
Table 4. GSK Major Business
Table 5. GSK Acute Migraine Drugs Product and Services
Table 6. GSK Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. GSK Recent Developments/Updates
Table 8. Teva Basic Information, Manufacturing Base and Competitors
Table 9. Teva Major Business
Table 10. Teva Acute Migraine Drugs Product and Services
Table 11. Teva Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Teva Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Acute Migraine Drugs Product and Services
Table 16. Pfizer Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer Recent Developments/Updates
Table 18. Novartis Basic Information, Manufacturing Base and Competitors
Table 19. Novartis Major Business
Table 20. Novartis Acute Migraine Drugs Product and Services
Table 21. Novartis Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Novartis Recent Developments/Updates
Table 23. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 24. Sun Pharma Major Business
Table 25. Sun Pharma Acute Migraine Drugs Product and Services
Table 26. Sun Pharma Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Sun Pharma Recent Developments/Updates
Table 28. Grunenthal Basic Information, Manufacturing Base and Competitors
Table 29. Grunenthal Major Business
Table 30. Grunenthal Acute Migraine Drugs Product and Services
Table 31. Grunenthal Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Grunenthal Recent Developments/Updates
Table 33. Endo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Endo Pharmaceuticals Major Business
Table 35. Endo Pharmaceuticals Acute Migraine Drugs Product and Services
Table 36. Endo Pharmaceuticals Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Endo Pharmaceuticals Recent Developments/Updates
Table 38. Merck Basic Information, Manufacturing Base and Competitors
Table 39. Merck Major Business
Table 40. Merck Acute Migraine Drugs Product and Services
Table 41. Merck Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Merck Recent Developments/Updates
Table 43. J & J Basic Information, Manufacturing Base and Competitors
Table 44. J & J Major Business
Table 45. J & J Acute Migraine Drugs Product and Services
Table 46. J & J Acute Migraine Drugs Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. J & J Recent Developments/Updates
Table 48. Global Acute Migraine Drugs Sales Quantity by Manufacturer (2018-2023) & (K Unit)
Table 49. Global Acute Migraine Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 50. Global Acute Migraine Drugs Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 51. Market Position of Manufacturers in Acute Migraine Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 52. Head Office and Acute Migraine Drugs Production Site of Key Manufacturer
Table 53. Acute Migraine Drugs Market: Company Product Type Footprint
Table 54. Acute Migraine Drugs Market: Company Product Application Footprint
Table 55. Acute Migraine Drugs New Market Entrants and Barriers to Market Entry
Table 56. Acute Migraine Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Acute Migraine Drugs Sales Quantity by Region (2018-2023) & (K Unit)
Table 58. Global Acute Migraine Drugs Sales Quantity by Region (2024-2029) & (K Unit)
Table 59. Global Acute Migraine Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 60. Global Acute Migraine Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 61. Global Acute Migraine Drugs Average Price by Region (2018-2023) & (USD/Unit)
Table 62. Global Acute Migraine Drugs Average Price by Region (2024-2029) & (USD/Unit)
Table 63. Global Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 64. Global Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 65. Global Acute Migraine Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 66. Global Acute Migraine Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 67. Global Acute Migraine Drugs Average Price by Type (2018-2023) & (USD/Unit)
Table 68. Global Acute Migraine Drugs Average Price by Type (2024-2029) & (USD/Unit)
Table 69. Global Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 70. Global Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 71. Global Acute Migraine Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 72. Global Acute Migraine Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 73. Global Acute Migraine Drugs Average Price by Application (2018-2023) & (USD/Unit)
Table 74. Global Acute Migraine Drugs Average Price by Application (2024-2029) & (USD/Unit)
Table 75. North America Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 76. North America Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 77. North America Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 78. North America Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 79. North America Acute Migraine Drugs Sales Quantity by Country (2018-2023) & (K Unit)
Table 80. North America Acute Migraine Drugs Sales Quantity by Country (2024-2029) & (K Unit)
Table 81. North America Acute Migraine Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 82. North America Acute Migraine Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 83. Europe Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 84. Europe Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 85. Europe Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 86. Europe Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 87. Europe Acute Migraine Drugs Sales Quantity by Country (2018-2023) & (K Unit)
Table 88. Europe Acute Migraine Drugs Sales Quantity by Country (2024-2029) & (K Unit)
Table 89. Europe Acute Migraine Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Acute Migraine Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 92. Asia-Pacific Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 93. Asia-Pacific Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 94. Asia-Pacific Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 95. Asia-Pacific Acute Migraine Drugs Sales Quantity by Region (2018-2023) & (K Unit)
Table 96. Asia-Pacific Acute Migraine Drugs Sales Quantity by Region (2024-2029) & (K Unit)
Table 97. Asia-Pacific Acute Migraine Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 98. Asia-Pacific Acute Migraine Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 99. South America Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 100. South America Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 101. South America Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 102. South America Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 103. South America Acute Migraine Drugs Sales Quantity by Country (2018-2023) & (K Unit)
Table 104. South America Acute Migraine Drugs Sales Quantity by Country (2024-2029) & (K Unit)
Table 105. South America Acute Migraine Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 106. South America Acute Migraine Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 107. Middle East & Africa Acute Migraine Drugs Sales Quantity by Type (2018-2023) & (K Unit)
Table 108. Middle East & Africa Acute Migraine Drugs Sales Quantity by Type (2024-2029) & (K Unit)
Table 109. Middle East & Africa Acute Migraine Drugs Sales Quantity by Application (2018-2023) & (K Unit)
Table 110. Middle East & Africa Acute Migraine Drugs Sales Quantity by Application (2024-2029) & (K Unit)
Table 111. Middle East & Africa Acute Migraine Drugs Sales Quantity by Region (2018-2023) & (K Unit)
Table 112. Middle East & Africa Acute Migraine Drugs Sales Quantity by Region (2024-2029) & (K Unit)
Table 113. Middle East & Africa Acute Migraine Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 114. Middle East & Africa Acute Migraine Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 115. Acute Migraine Drugs Raw Material
Table 116. Key Manufacturers of Acute Migraine Drugs Raw Materials
Table 117. Acute Migraine Drugs Typical Distributors
Table 118. Acute Migraine Drugs Typical Customers
List of Figures
Figure 1. Acute Migraine Drugs Picture
Figure 2. Global Acute Migraine Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Acute Migraine Drugs Consumption Value Market Share by Type in 2022
Figure 4. Triptans Examples
Figure 5. NSAIDs Examples
Figure 6. Others Examples
Figure 7. Global Acute Migraine Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Acute Migraine Drugs Consumption Value Market Share by Application in 2022
Figure 9. Hospital Pharmacies Examples
Figure 10. Drug Stores Examples
Figure 11. Global Acute Migraine Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Acute Migraine Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Acute Migraine Drugs Sales Quantity (2018-2029) & (K Unit)
Figure 14. Global Acute Migraine Drugs Average Price (2018-2029) & (USD/Unit)
Figure 15. Global Acute Migraine Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Acute Migraine Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Acute Migraine Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Acute Migraine Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Acute Migraine Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Acute Migraine Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Acute Migraine Drugs Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Acute Migraine Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Acute Migraine Drugs Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Acute Migraine Drugs Average Price by Type (2018-2029) & (USD/Unit)
Figure 30. Global Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Acute Migraine Drugs Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Acute Migraine Drugs Average Price by Application (2018-2029) & (USD/Unit)
Figure 33. North America Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Acute Migraine Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Acute Migraine Drugs Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Acute Migraine Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Acute Migraine Drugs Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Acute Migraine Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Acute Migraine Drugs Consumption Value Market Share by Region (2018-2029)
Figure 53. China Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Acute Migraine Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Acute Migraine Drugs Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Acute Migraine Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Acute Migraine Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Acute Migraine Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Acute Migraine Drugs Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Acute Migraine Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Acute Migraine Drugs Market Drivers
Figure 74. Acute Migraine Drugs Market Restraints
Figure 75. Acute Migraine Drugs Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Acute Migraine Drugs in 2022
Figure 78. Manufacturing Process Analysis of Acute Migraine Drugs
Figure 79. Acute Migraine Drugs Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
